Drug Profile

SENS 03

Alternative Names: SENS-03

Latest Information Update: 02 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sensorium Therapeutics
Class Antiepileptic drugs
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Preclinical Epilepsy

Most Recent Events

02 Mar 2026 Sensorium plans to declare a development candidate for SENS 03 program in second quarter of 2026 (Sensorium Therapeutics pipeline, March 2026)
10 Oct 2024 Preclinical trials in Epilepsy in USA (unspecified route)
06 Aug 2024 Early research in Epilepsy in USA (unspecified route) prior to August 2024 (Sensorium Therapeutics pipeline, August 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com